{"name":"Alexion Pharmaceuticals, Inc.","slug":"alexion-pharmaceuticals-inc","ticker":"","exchange":"","domain":"alexion.com","description":"","hq":"Cheshire","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":3082000000,"revenueGrowth":18.4,"grossMargin":0,"rdSpend":886000000,"netIncome":603400000,"cash":18103000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":34,"colorKey":"oncology","drugs":[{"name":"ACH-0145228: Powder-in-capsule","genericName":"ACH-0145228: Powder-in-capsule","slug":"ach-0145228-powder-in-capsule","indication":"Other","status":"phase_1"},{"name":"ACH-0145228: Immediate Release","genericName":"ACH-0145228: Immediate Release","slug":"ach-0145228-immediate-release","indication":"Other","status":"phase_1"},{"name":"ALXN1920","genericName":"ALXN1920","slug":"alxn1920","indication":"Other","status":"phase_2"},{"name":"ALXN2050 MR Prototype Tablet","genericName":"ALXN2050 MR Prototype Tablet","slug":"alxn2050-mr-prototype-tablet","indication":"Other","status":"phase_1"},{"name":"ALXN2420","genericName":"ALXN2420","slug":"alxn2420","indication":"Other","status":"phase_2"},{"name":"ACH-0143102","genericName":"ACH-0143102","slug":"ach-0143102","indication":"Other","status":"phase_1"},{"name":"ACH-0145228","genericName":"ACH-0145228","slug":"ach-0145228","indication":"Other","status":"phase_1"},{"name":"ACH-126,443","genericName":"ACH-126,443","slug":"ach-126-443","indication":"Other","status":"phase_2"},{"name":"ALXN1007","genericName":"ALXN1007","slug":"alxn1007","indication":"Other","status":"phase_1"},{"name":"ALXN1210","genericName":"ALXN1210","slug":"alxn1210","indication":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"phase_1"},{"name":"ALXN1210 IV","genericName":"ALXN1210 IV","slug":"alxn1210-iv","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_1"},{"name":"ALXN1210 SC","genericName":"ALXN1210 SC","slug":"alxn1210-sc","indication":"Other","status":"phase_1"},{"name":"ALXN1720","genericName":"ALXN1720","slug":"alxn1720","indication":"Other","status":"phase_1"},{"name":"ALXN1720 IV","genericName":"ALXN1720 IV","slug":"alxn1720-iv","indication":"Other","status":"phase_1"},{"name":"ALXN1720 SC","genericName":"ALXN1720 SC","slug":"alxn1720-sc","indication":"Other","status":"phase_1"},{"name":"ALXN1820 IV","genericName":"ALXN1820 IV","slug":"alxn1820-iv","indication":"Other","status":"phase_1"},{"name":"ALXN1820 SC","genericName":"ALXN1820 SC","slug":"alxn1820-sc","indication":"Other","status":"phase_1"},{"name":"ALXN1840 Enteric-coated Tablet","genericName":"ALXN1840 Enteric-coated Tablet","slug":"alxn1840-enteric-coated-tablet","indication":"Other","status":"phase_1"},{"name":"ALXN1840 Non-coated Capsule","genericName":"ALXN1840 Non-coated Capsule","slug":"alxn1840-non-coated-capsule","indication":"Other","status":"phase_1"},{"name":"ALXN1910","genericName":"ALXN1910","slug":"alxn1910","indication":"Other","status":"phase_1"},{"name":"ALXN2030","genericName":"ALXN2030","slug":"alxn2030","indication":"Mucopolysaccharidosis type I (MPS I)","status":"phase_2"},{"name":"ALXN2040","genericName":"ALXN2040","slug":"alxn2040","indication":"Other","status":"phase_1"},{"name":"ALXN2050 MR Prototype Mini-Tablet","genericName":"ALXN2050 MR Prototype Mini-Tablet","slug":"alxn2050-mr-prototype-mini-tablet","indication":"Other","status":"phase_1"},{"name":"ALXN2060","genericName":"ALXN2060","slug":"alxn2060","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_3"},{"name":"ALXN2080","genericName":"ALXN2080","slug":"alxn2080","indication":"Other","status":"phase_1"},{"name":"ALXN2230","genericName":"ALXN2230","slug":"alxn2230","indication":"Other","status":"phase_1"},{"name":"ALXN2350","genericName":"ALXN2350","slug":"alxn2350","indication":"Other","status":"phase_1"},{"name":"AZP-3601","genericName":"AZP-3601","slug":"azp-3601","indication":"Other","status":"phase_1"},{"name":"Bis-Choline Tetrathiomolybdate","genericName":"Bis-Choline Tetrathiomolybdate","slug":"bis-choline-tetrathiomolybdate","indication":"Wilson's disease","status":"phase_2"},{"name":"C5 Inhibitor","genericName":"C5 Inhibitor","slug":"c5-inhibitor","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_3"},{"name":"CAEL-101","genericName":"CAEL-101","slug":"cael-101","indication":"Transthyretin cardiac amyloidosis (ATTR-CM)","status":"phase_3"},{"name":"Danicopan - LFC","genericName":"Danicopan - LFC","slug":"danicopan-lfc","indication":"Other","status":"phase_1"},{"name":"Ultomiris","genericName":"Ultomiris","slug":"ultomiris","indication":"Atypical hemolytic uremic syndrome (aHUS)","status":"marketed"},{"name":"pexelizumab in conjunction with CABG","genericName":"pexelizumab in conjunction with CABG","slug":"pexelizumab-in-conjunction-with-cabg","indication":"Cardiac surgery for reduction of mortality and morbidity","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ACH-0144471","genericName":"ACH-0144471","slug":"ach-0144471","indication":"Systemic lupus erythematosus","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ALXN1850","genericName":"ALXN1850","slug":"alxn1850","indication":"C3 glomerulopathy","status":"phase_3"}]}],"pipeline":[{"name":"ACH-0145228: Powder-in-capsule","genericName":"ACH-0145228: Powder-in-capsule","slug":"ach-0145228-powder-in-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACH-0145228: Immediate Release","genericName":"ACH-0145228: Immediate Release","slug":"ach-0145228-immediate-release","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1920","genericName":"ALXN1920","slug":"alxn1920","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2050 MR Prototype Tablet","genericName":"ALXN2050 MR Prototype Tablet","slug":"alxn2050-mr-prototype-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2420","genericName":"ALXN2420","slug":"alxn2420","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACH-0143102","genericName":"ACH-0143102","slug":"ach-0143102","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACH-0144471","genericName":"ACH-0144471","slug":"ach-0144471","phase":"phase_2","mechanism":"ACH-0144471 is a monoclonal antibody targeting the CD40 receptor.","indications":["Systemic lupus erythematosus"],"catalyst":""},{"name":"ACH-0145228","genericName":"ACH-0145228","slug":"ach-0145228","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACH-126,443","genericName":"ACH-126,443","slug":"ach-126-443","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1007","genericName":"ALXN1007","slug":"alxn1007","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1210","genericName":"ALXN1210","slug":"alxn1210","phase":"phase_1","mechanism":"Complement inhibitor","indications":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"catalyst":""},{"name":"ALXN1210 IV","genericName":"ALXN1210 IV","slug":"alxn1210-iv","phase":"phase_1","mechanism":"ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","Atypical hemolytic uremic syndrome (aHUS)"],"catalyst":""},{"name":"ALXN1210 SC","genericName":"ALXN1210 SC","slug":"alxn1210-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1720","genericName":"ALXN1720","slug":"alxn1720","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1720 IV","genericName":"ALXN1720 IV","slug":"alxn1720-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1720 SC","genericName":"ALXN1720 SC","slug":"alxn1720-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1820 IV","genericName":"ALXN1820 IV","slug":"alxn1820-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1820 SC","genericName":"ALXN1820 SC","slug":"alxn1820-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1840 Enteric-coated Tablet","genericName":"ALXN1840 Enteric-coated Tablet","slug":"alxn1840-enteric-coated-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1840 Non-coated Capsule","genericName":"ALXN1840 Non-coated Capsule","slug":"alxn1840-non-coated-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN1850","genericName":"ALXN1850","slug":"alxn1850","phase":"phase_3","mechanism":"ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.","indications":["C3 glomerulopathy","Post-infectious glomerulonephritis"],"catalyst":""},{"name":"ALXN1910","genericName":"ALXN1910","slug":"alxn1910","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2030","genericName":"ALXN2030","slug":"alxn2030","phase":"phase_2","mechanism":"ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy.","indications":["Mucopolysaccharidosis type I (MPS I)"],"catalyst":""},{"name":"ALXN2040","genericName":"ALXN2040","slug":"alxn2040","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2050 MR Prototype Mini-Tablet","genericName":"ALXN2050 MR Prototype Mini-Tablet","slug":"alxn2050-mr-prototype-mini-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2060","genericName":"ALXN2060","slug":"alxn2060","phase":"phase_3","mechanism":"ALXN2060 is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","C3 glomerulopathy"],"catalyst":""},{"name":"ALXN2080","genericName":"ALXN2080","slug":"alxn2080","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2230","genericName":"ALXN2230","slug":"alxn2230","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALXN2350","genericName":"ALXN2350","slug":"alxn2350","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AZP-3601","genericName":"AZP-3601","slug":"azp-3601","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bis-Choline Tetrathiomolybdate","genericName":"Bis-Choline Tetrathiomolybdate","slug":"bis-choline-tetrathiomolybdate","phase":"phase_2","mechanism":"Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.","indications":["Wilson's disease"],"catalyst":""},{"name":"C5 Inhibitor","genericName":"C5 Inhibitor","slug":"c5-inhibitor","phase":"phase_3","mechanism":"A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","Atypical hemolytic uremic syndrome (aHUS)","Generalized myasthenia gravis (gMG)","C3 glomerulopathy"],"catalyst":""},{"name":"CAEL-101","genericName":"CAEL-101","slug":"cael-101","phase":"phase_3","mechanism":"CAEL-101 is a transthyretin (TTR) stabilizer that binds to and stabilizes the transthyretin protein, preventing its misfolding and amyloid fibril formation.","indications":["Transthyretin cardiac amyloidosis (ATTR-CM)","Hereditary transthyretin amyloidosis (hATTR)"],"catalyst":""},{"name":"Danicopan - LFC","genericName":"Danicopan - LFC","slug":"danicopan-lfc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ultomiris","genericName":"Ultomiris","slug":"ultomiris","phase":"marketed","mechanism":"Complement C5","indications":["Atypical hemolytic uremic syndrome (aHUS)","Generalized myasthenia gravis","Myasthenia gravis","Paroxysmal nocturnal hemoglobinuria"],"catalyst":""},{"name":"pexelizumab in conjunction with CABG","genericName":"pexelizumab in conjunction with CABG","slug":"pexelizumab-in-conjunction-with-cabg","phase":"phase_3","mechanism":"Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.","indications":["Cardiac surgery for reduction of mortality and morbidity"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVndfTDhnYThsOWRvdk9pc0pyZndPLXVGYkJHd2podXBLNnltMFYxdzV0bXVvN3pfalVLcXhua3o0R0E5SUlRaldsbWktRkIwSkZBWGZzMjFwS2hXdFFYRXVubDV0RnFlNnY1NEVyZUFtZkJCUEVuaTlaN1BqZ0ZUbFd6THd2dk5PVFNJNXdDZkNuOHPSAVZBVV95cUxQcG1oQU5fYk1ZQlRyVTQtbHhkMjRkNFc3T2sydXZMVGppUW5Pb09Idjd1cGxaR25CbXhpeDRfRkZXbWxRbGJMcUR2Q24wTTU0MWlGdkttZw?oc=5","date":"2026-04-02","type":"pipeline","source":"Law360","summary":"Alexion Beats Trade Secret Claims In Amyndas Suit - Law360","headline":"Alexion Beats Trade Secret Claims In Amyndas Suit - Law360","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-09","type":"pipeline","source":"ET Pharma","summary":"AstraZeneca launches rare blood, kidney disease drug Eculizumab in India - ET Pharma","headline":"AstraZeneca launches rare blood, kidney disease drug Eculizumab in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowNBVV95cUxOYjdySC02eVo0SEpSaW9LSGFSdW9mOTUzNV9sSGdsN1VUVjZ2WmkwOHFJMTBKMzZoc0VQNVF1MXloRFZqSDZiNFN1ZVBTblpiY0Y2Vlg0VHNXcVpWWXQ0Rk1sbG83dkIxZlcwdHdLWjRmUlJENFhIbmtkNEZiMmdGMjU4V2JueGdZelNPbU1DYkNiMlExMXhZbUI4ZXdKNGxndndLRmlkc1JzX0EzdUwtcHNLWlNZM1dDaXNkMVViWlQ1WHJkeXJYRUhLalRqWmNObkJOdTR4TU0xZThsQTcxVWljeTVjMUphSXFCZUdrekRsX0pYbkdvUElvdW1vQTgtdVhnUlVjQTBORGhtenB1bFlMMjhPWnM2aVlWWU40SExSUUsyMW8tMXRKYXFxRkRKdm1ZNF8zd0hONWZEWGRYdEprNEdpWW5hNURDaFZmbktDSFBmMUlqQ2pjc1FKendEM2dhRWFUTkZqOEE5dWwwU1N0bEhENjR2Umdrb0NJbHl5cmdZbXJWQlBneUNzb09pQlFEaGYxVU52clB5U1JkUmFqSQ?oc=5","date":"2025-08-07","type":"pipeline","source":"Newswire Canada","summary":"Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD","headline":"Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQWWNMaGo4VWRaZnJ0bEpfcnl5OFAxYnFBekVlYXVpZ3JjbDBOam1FbFlld0otTGcxc1ZTODNtTU9TNGp2Q0c0LUw0SVR3VFhCMFNfbWRGRHE1OUNrZUdON0xsWGJNMGNpX19WTGYySDhEQVhoVzBOM1BldXhhakpWWnNmdnp5SkpNUE9XQ0lPZUgzZGdnMTFqUzF6Qjh1ZVE?oc=5","date":"2025-07-24","type":"trial","source":"BioPharma Dive","summary":"AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial - BioPharma Dive","headline":"AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5UUEtQTER5cUtFWUZPbTM2MmgxaGFydzUzMkVkdTluWHA5Y2FjcjUzckpCWV91OFByR0Y2SGs1UjdkSWxZN1RkNHMySWIyOXFWVk9kZUszYnVoU1JybXlGTnZ1NnJVUQ?oc=5","date":"2025-03-18","type":"pipeline","source":"Built In","summary":"10 Pharmaceutical Companies in France to Know - Built In","headline":"10 Pharmaceutical Companies in France to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNWW1JTG83Qy1BTWx1dGxJaTBTX0FjM0FLRll3XzkxOXQ0bjl6QVpVUmNkdmx5UlR0WTNvaE13YWZrQUVhbVlTM1JiWmtFajAzYVQ4TmphYkEtYXp3YnJXNkVlX3ZVLWZuZnVzQVJYd05zQ1hZMUdaM2dhd25nWkJ2aDlhZzZPRFpZN1E?oc=5","date":"2023-06-26","type":"pipeline","source":"marketscreener.com","summary":"Alexion Pharmaceuticals, Inc.: Shareholders Board Members Managers and Company Profile | US0153511094 - marketscreener.com","headline":"Alexion Pharmaceuticals, Inc.: Shareholders Board Members Managers and Company Profile | US0153511094","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQLTNBODRvN1ZnMUhXMGVjZ0hZc2JIY0s4dGFkNEpMRGNEZzhCUy1PWExHOV9mLVl3SHFrVnc1QjBWcjh4Rk9Kb3FEQWFZYU15ZEExMURZXzByT1N1OUFGeFB0TUZKcFhwSjhGOU9tX056bUNoQlJYTXN0eFktNDhQWGx1dGp1NHEzaTJhN2h1bnZNWnM1NHhCVFRJNE90SnQ4TV9MTlNaRGRSYVNNQWVobHV3MmVkZWprVWVIVw?oc=5","date":"2022-06-27","type":"pipeline","source":"European Pharmaceutical Review","summary":"Alexion to expand biologics manufacturing with €65m investment - European Pharmaceutical Review","headline":"Alexion to expand biologics manufacturing with €65m investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNQjlFT2UtdXh4TWhJMXdTM0w5V1FlWUp3cFZVQXEwWW05MGZnazFsRWl6UGUxMjdidXNCZ0JsRkZsc0lSVGxQN0F6eTZPdmRPNTlEU0lQUG1Bbl9xcXlzLXBodTVEWDgtMlhtVjVaRDczZFlMNnZ4X1c5cXRxQ1UzNlB5OU1fXzFYSVZlTmxVLUNhb2FQRGFPQzNJTnFCN3pfZlI1NG1PRXNSNTlpeW9DdmlWSmNrTTFYYWROdnRLTnRnUUc4dUE?oc=5","date":"2022-06-24","type":"pipeline","source":"Fierce Pharma","summary":"AstraZeneca chips in another $68.7M to beef up Alexion's manufacturing capabilities in Ireland - Fierce Pharma","headline":"AstraZeneca chips in another $68.7M to beef up Alexion's manufacturing capabilities in Ireland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOUzRBZlNJaDJZMDdpQkhWbGNtcEhQa1dTMWtMeFM3UUp4MGt2M2ZZcVg1dkdTWHJsZUd6YTZFWFJ0S3RoNkFaeGMxVmt4SFdyTnQ2QkY0VzJrSWhRWTZ5Y3dKbnRiVlBWcVVCSXI0NlRsbS1tR1dHdU9JRUdSN2l2N2dYUjNlUQ?oc=5","date":"2021-07-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"AstraZeneca concludes Alexion acquisition for $39bn - Pharmaceutical Technology","headline":"AstraZeneca concludes Alexion acquisition for $39bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOMGZoY3IwRm1tczNLODZOOFM4MlZpM2tsVmM2R3lvX1hrY0JoY1h2bk5ucWdfek1md1VEN1oxSWw2NnZYbF8wRFdoQXQ2TTgzZTc5RXFSOVhDOGlEdG41YlIzcEJ2cEgtSS02dWJ2S0VzejQ3NzRMR2FtMUtKMVVGaGR2Vm9PMFdtTVFHdmtLMm9qeHd3QW1HZDdPbmJqZGs?oc=5","date":"2021-07-21","type":"pipeline","source":"AstraZeneca","summary":"Acquisition of Alexion completed - AstraZeneca","headline":"Acquisition of Alexion completed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQMFhRZ1RfelFzRUxCd1VLZC1CeUtFUWsxZ1ZnWDFjRHNDdW5fTnJIc2hweXcwNUFsME1vVDBaWlZkSGpvTFVLT2NnWW8ta3NjVjNQbU1tOGlVRFFuSUFPVzUtbHJxUVViX1lETEVVbm9WUGVmVzd6Z0ZiUGt5RHNCOGJxWHJnems0Mld2VXRKVXNIakphZHc?oc=5","date":"2021-02-04","type":"pipeline","source":"SEC.gov","summary":"Document - SEC.gov","headline":"Document","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxOTS1EakhJTlc1N29xRDBLZjlBZ2VpeWZJUGVaaFNzUmtnLXZRT3kwNGtiU0Y0ZGU3bm5ZcHo2SVRvUVpkQUwxWmRIaU03YTRHaFVKTnFyMWRhRldON0NRMGJnRWNFd01UYTY2RjJZak9ReGJhd3ZmdHRKSlVXUHoySXpLaXhCZUZfS3Q1UkpOWHQwMXpNS1lmS1FvdElNZkJWczVOM1hFTDlwSEpTVjZUNFVLV3VzckU3MUc1ODFxUmtXSm1DMHg1blpQYUt6dTBYallZS1JVZEFybi1GcHZLc2lqXzU2eWhXcEZnM3diYVVrOURjWVpXQ0hlQnRYVFBJSWhZakhhOHFQaTBxaGNZOTBwdzMybkMwMTF4WWZ3QW45XzdCTEo1c0VveEJvU19ScVpPcHRiazNfQ0JVWlVqQ1VNOEVXc3JlTkE?oc=5","date":"2018-06-11","type":"deal","source":"PR Newswire","summary":"BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy - PR Newswire","headline":"BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Orig","sentiment":"neutral"}],"patents":[],"drugCount":36,"phaseCounts":{"phase_1":24,"phase_2":6,"phase_3":5,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":3082000000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":3082000000,"period":"2016-12-31"},{"value":2602532000,"period":"2015-12-31"},{"value":2603000000,"period":"2015-12-31"},{"value":2233733000,"period":"2014-12-31"},{"value":2233733000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":886000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":603400000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":18103000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}